Cardioprotective effects of extracellular vesicles from hypoxia-preconditioned mesenchymal stromal cells in experimental pulmonary arterial hypertension.

Authors

Renata Trabach Santos, Cássia Lisboa Braga, Maria Eduarda de Sá Freire Onofre, Carla Medeiros da Silva, Nazareth de Novaes Rocha, Rodrigo Gonzaga Veras, Sabrina Sodré de Souza Serra, Douglas Esteves Teixeira, Sarah Aparecida Dos Santos Alves, Beatriz Toja Miranda, Miria Gomes Pereira, Celso Caruso Neves, Monique Ramos de Oliveira Garcia, Christina Maeda Takiya, Patricia Rieken Macêdo Rocco, Fernanda Ferreira Cruz, Pedro Leme Silva

Published in

Stem cell research & therapy. Volume 16. Issue 1. Pages 466. Aug 29, 2025. Epub Aug 29, 2025.

Abstract

During pulmonary arterial hypertension (PAH), cardiac cells develop a hypertrophic and apoptosis-resistant phenotype. Mesenchymal stromal cell (MSC) therapy has been shown to mitigate pulmonary vascular remodeling in PAH; however, successful application is limited by low potency and the need for a high number of MSCs. MSCs exposed to hypoxia release more extracellular vesicles (EV)s with different content than normoxia. We aimed to evaluate the proteomic profile and therapeutic effects of EVs derived from normoxia- and hypoxia-preconditioned MSCs on cardiac tissue remodeling in experimental PAH.
Isolated bone marrow MSCs were subjected to normoxia (N, 21%O₂) or hypoxia (H, 1%O₂) for 48 h and EVs were collected from the MSCs by ultracentrifugation. Proteomic data of the EVs were reanalyzed using PatternLab for Proteomics 5.0. Thirty-two male Wistar rats were randomly assigned to PAH plus intraperitoneal monocrotaline (60 mg/kg) or control (CTRL) with saline. On day 14, PAH animals received saline (1 mL/kg; PAH-SAL), EV-N (EVs from 1 × 10⁶ MSCs; PAH-EV-N) or EV-H (EVs from 1 × 10⁶ MSCs; PAH-EV-H) by jugular vein. On day 28, right ventricular systolic pressure (RVSP), pulmonary acceleration time/pulmonary ejection time (PAT/PET) ratio, right ventricle (RV) outflow diameter, and right ventricular hypertrophy (RVH) index were evaluated. The heart was harvested for histologic and molecular biology analyses.
Among 695 proteins identified, 203 were present only in EV-H and 51 in EV-N. EV-H was enriched in proteins involved in the negative regulation of mitogen-activated protein kinase and apoptosis pathways. On day 28, both EV-N and EV-H therapies decreased RVSP compared with PAH-SAL (32 ± 5 mmHg and 29 ± 4 mmHg versus 39 ± 2 mmHg; p < 0.01). Only EV-H increased PAT/PET, reduced RV outflow diameter, and the RVH index compared with PAH-SAL. The expressions of c-Myc, a marker of myocardial injury, and p-GSK3β-Ser9, a proliferative marker, were higher in the PAH-SAL group than in the CTRL group. EV-N and EV-H decreased c-Myc expression, but only EV-H significantly reduced p-GSK3β-Ser9.
EV-N and EV-H reduced RVSP, but only EV-H improved RVH and RV outflow diameter, increased the PAT/PET ratio, and downregulated GSK3β protein levels. EVs from hypoxia-preconditioned MSCs demonstrated greater cardioprotective effects than those from normoxia-conditioned MSCs.

PMID:
40877897
Bibliographic data and abstract were imported from PubMed on 29 Aug 2025.

Read full publication at:
Please sign in to see all details.

Sign up!

Did you like this publication? Sign up with Life Science Network.
If you already have a Life Science Network account, sign in, or connect with LinkedIn, Google.

Stats

Community rating n/a 0 votes
Reviewers' rating n/a 0 votes

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Recommendations n/a n/a positive of 0 vote(s)
Views 2
Comments 0

Comments

There are no comments yet.